CYBB (NADPH oxidase 2) variants and mutations
CYBB (also known as NADPH oxidase 2) is a human protein-coding gene encoding a NADPH oxidase 2 protein. It generates the catalytic electron flow that allows phagocytes to produce microbicidal reactive oxygen species during the respiratory burst. Loss-of-function variants cause X-linked chronic granulomatous disease with severe susceptibility to bacterial and fungal infection. This analysis covers 743 CYBB variants and mutations. Of these, 71% have computational variant effect predictions. Disease context includes chronic granulomatous disease, neurodegenerative disease, and hereditary disease. Example CYBB variants include M1?, M1I, and M1V.
Variant analysis overview
- Gene: CYBB
- Protein: NADPH oxidase 2
- UniProt accession: P04839
- Organism: Homo sapiens
- Variants analyzed: 743
- Variant scope: all variants
- Completed: 2026-08-18
Variant and mutation evidence
- Variant composition: 535 unspecified-consequence records; 86 synonymous variants; 98 missense variants; 7 splice-region variants; 4 frameshift variants; 6 stop-gained variants; 1 in-frame deletions; 6 substitution
- Prediction scores: 529 variants have prediction scores (71% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: chronic granulomatous disease, neurodegenerative disease, hereditary disease, discoid lupus erythematosus, Recurrent bronchitis, primary ciliary dyskinesia, Dynein arm defect of respiratory motile cilia, diabetes mellitus, systemic lupus erythematosus, neoplasm, Parkinson disease, acute myeloid leukemia.
Protein structure and variant hotspots
- Protein features: 6 transmembrane segments; 2 domains; 24 binding sites; 3 post-translational modification sites.
- Structural context: 548 variants have structural context.
- PTM context: 1 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, ClinGen, MaveDB, LitVar.
Notable CYBB variants
Examples include M1?, M1I, M1V, G2G, N3T, W4*, W4R, V6A. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- M1?, NCI-TCGA Cosmic COSV6608, Variant assessed as somatic; high impact.
- M1I (p.Met1Ile), rs2146801939, ClinGen CA412971898, ClinVar RCV001390154, MetaLR 0.95, MetaSVM 1.10, Pathogenic, Granulomatous disease, chronic, X-linked
- M1V (p.Met1Val), rs2146801935, ClinGen CA412971887, ClinVar RCV001560032, ClinVar RCV004594361, MetaLR 0.95, MetaSVM 1.10, Pathogenic, Granulomatous disease, chronic, X-linked; not provided
- G2G (p.Gly2Gly), rs372462475, gnomAD X-37780083-G-C, CADD 10.60
- N3T (p.Asn3Thr), rs782014879, ClinGen CA10383624, ClinVar RCV001322718, ClinVar RCV001830977, REVEL 0.59, CADD 21.50, Conflicting interpretations, Inborn genetic diseases; Granulomatous disease, chronic, X-linked
- W4* (p.Trp4Ter), rs2146801959, ClinGen CA412971921, ClinVar RCV001916148, Ensembl rs2146801959, Pathogenic
- W4R (p.Trp4Arg), rs782495755, 1000Genomes rs782495755, ExAC rs782495755, TOPMed rs782495755, REVEL 0.84, CADD 24.30, Benign, Granulomatous disease, chronic, X-linked
- V6A (p.Val6Ala), rs2519189211, ClinGen CA412971938, ClinVar RCV003622461, NCI-TCGA TCGA novel, Uncertain significance, Granulomatous disease, chronic, X-linked
- V6M (p.Val6Met), gnomAD X-37780093-G-A, REVEL 0.51, CADD 24.00
- V6E (p.Val6Glu), gnomAD X-37780094-T-A, REVEL 0.37, CADD 19.60
- V6V (p.Val6Val), gnomAD X-37780095-G-A, CADD 9.55
- N7H (p.Asn7His), rs1890282710, ClinGen CA412971946, ClinVar RCV003855775, Ensembl rs1890282710, AlphaMissense 0.55, MetaLR 0.93, Uncertain significance, Granulomatous disease, chronic, X-linked
- N7S (p.Asn7Ser), TOPMed rs1928915980, REVEL 0.78, CADD 25.30
- E8E (p.Glu8Glu), gnomAD X-37780101-G-A, CADD 6.45
- G9G (p.Gly9Gly), rs979166608, gnomAD X-37780104-G-T, CADD 2.82
- L10I (p.Leu10Ile), gnomAD X-37780105-C-A, REVEL 0.34, CADD 14.60
- L10F (p.Leu10Phe), gnomAD X-37780105-C-T, REVEL 0.40, CADD 14.90
- L10L (p.Leu10Leu), rs781966553, gnomAD X-37780107-C-T, CADD 9.38
- S11F (p.Ser11Phe), rs1373814247, ClinGen CA412972012, ClinVar RCV003879026, Ensembl rs1373814247, REVEL 0.83, CADD 26.20, Uncertain significance, Granulomatous disease, chronic, X-linked
- I12L (p.Ile12Leu), rs797044560, ClinGen CA236343, ClinVar RCV000171434, Ensembl rs797044560, AlphaMissense 0.11, MetaLR 0.63, Likely benign
- F13S (p.Phe13Ser), NCI-TCGA Cosmic COSV6608, Variant assessed as somatic; moderate impact.
- F13F (p.Phe13Phe), rs782135438, gnomAD X-37780116-T-C, CADD 11.60
- V14A (p.Val14Ala), TOPMed rs1556464121, gnomAD rs1556464121, REVEL 0.80, CADD 25.40
- V14V (p.Val14Val), rs1928916724, gnomAD X-37780119-C-A, CADD 11.10
- I15F (p.Ile15Phe), rs781809179, ClinGen CA412972056, ClinVar RCV001319779, ClinVar RCV001835601, REVEL 0.56, CADD 17.20, Uncertain significance, Granulomatous disease, chronic, X-linked
- I15T (p.Ile15Thr), TOPMed rs1928917046, REVEL 0.66, CADD 24.10
- I15V (p.Ile15Val), rs781809179, ClinGen CA10383629, ClinVar RCV001490183, ClinVar RCV001832638, REVEL 0.29, CADD 9.65, Likely benign, Granulomatous disease, chronic, X-linked
- L16P (p.Leu16Pro), rs2146803094, ClinGen CA412972259, ClinVar RCV002243550, Ensembl rs2146803094, AlphaMissense 0.96, MetaLR 0.83, Uncertain significance, Granulomatous disease, chronic, X-linked
- L16L (p.Leu16Leu), gnomAD X-37782088-C-T, CADD 15.00
- V17A (p.Val17Ala), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- V17F (p.Val17Phe), gnomAD X-37782089-TG-T, CADD 22.70
- V17I (p.Val17Ile), gnomAD X-37782091-G-A, REVEL 0.27, CADD 12.40
- V17V (p.Val17Val), rs2146803096, gnomAD X-37782093-T-C, CADD 6.01
- W18C (p.Trp18Cys), UniProt VAR 047264, Pathogenic, in CGDX
- W18R (p.Trp18Arg), gnomAD X-37782094-T-C, REVEL 0.96, CADD 27.60
- L19M (p.Leu19Met), Ensembl rs1928963424
- L19P (p.Leu19Pro), gnomAD X-37782098-T-C, REVEL 0.88, CADD 27.50
- G20R (p.Gly20Arg), rs151344455, ClinGen CA412972321, NCI-TCGA Cosmic COSV1010, REVEL 0.89, CADD 26.50, Pathogenic, Granulomatous disease, chronic, X-linked
- G20G (p.Gly20Gly), gnomAD X-37782102-G-T, CADD 6.16
- L21S (p.Leu21Ser), rs2519190828, ClinGen CA412972345, ClinVar RCV002859782, Uncertain significance, Inborn genetic diseases
- L21V (p.Leu21Val), gnomAD rs1556464546
- N22K (p.Asn22Lys), rs193922450, ClinGen CA204475, ClinVar RCV000190516, 1000Genomes rs193922450, AlphaMissense 1.00, MetaLR 0.91, Uncertain significance, Granulomatous disease, chronic, X-linked
- N22S (p.Asn22Ser), rs2146803116, ClinGen CA412972362, ClinVar RCV002224679, Ensembl rs2146803116, AlphaMissense 0.76, MetaLR 0.92, Uncertain significance, not provided
- N22N (p.Asn22Asn), rs193922450, gnomAD X-37782108-C-T, AlphaMissense 1.00, MetaLR 0.91
- V23I (p.Val23Ile), rs781986436, ClinGen CA10383642, NCI-TCGA Cosmic COSV1010, ClinVar RCV003088597, REVEL 0.32, CADD 15.10, Likely benign, Granulomatous disease, chronic, X-linked
- F24L (p.Phe24Leu), NCI-TCGA Cosmic COSV1010, Variant assessed as somatic; moderate impact.
- L25I (p.Leu25Ile), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- L25V (p.Leu25Val), Ensembl rs2146803122
- L25F (p.Leu25Phe), gnomAD X-37782115-C-T, REVEL 0.81, CADD 25.30
- V27F (p.Val27Phe), rs782168000, NCI-TCGA Cosmic COSV1010, ExAC rs782168000, gnomAD rs782168000, REVEL 0.67, CADD 16.60, Variant assessed as somatic; moderate impact.
- V27L (p.Val27Leu), NCI-TCGA Cosmic COSV1010, Variant assessed as somatic; moderate impact.
- V27I (p.Val27Ile), gnomAD X-37782121-G-A, REVEL 0.23, CADD 9.33
- V27A (p.Val27Ala), gnomAD X-37782122-T-C, REVEL 0.47, CADD 18.90
- W28L (p.Trp28Leu), ExAC rs782408392
- W28S (p.Trp28Ser), rs782408392, ClinGen CA412972461, ClinVar RCV004367688, AlphaMissense 0.39, MetaLR 0.69, Uncertain significance, Inborn genetic diseases
- W28C (p.Trp28Cys), gnomAD X-37782126-G-T, REVEL 0.49, CADD 11.50
- Y29Y (p.Tyr29Tyr), rs1928964797, gnomAD X-37782129-T-C, CADD 6.61
- R31Q (p.Arg31Gln), TOPMed rs1186180772, gnomAD rs1186180772, REVEL 0.15, CADD 7.93, Uncertain significance, Granulomatous disease, chronic, X-linked
- R31W (p.Arg31Trp), rs1556464560, ClinGen CA412972513, NCI-TCGA Cosmic COSV1010, ClinVar RCV003073703, REVEL 0.22, CADD 13.20, Conflicting interpretations, Inborn genetic diseases; Granulomatous disease, chronic, X-linked
- R31P (p.Arg31Pro), gnomAD X-37782134-G-C, REVEL 0.40, CADD 2.77
- R31R (p.Arg31Arg), rs2146803145, gnomAD X-37782135-G-A, CADD 5.63
- Y33C (p.Tyr33Cys), gnomAD X-37782140-A-G, REVEL 0.87, CADD 23.90
- Y33Y (p.Tyr33Tyr), rs781937944, gnomAD X-37782141-T-C, CADD 6.56
- D34N (p.Asp34Asn), NCI-TCGA Cosmic COSV6608, Variant assessed as somatic; moderate impact.
- D34D (p.Asp34Asp), gnomAD X-37782144-T-C, CADD 1.39
- I35V (p.Ile35Val), NCI-TCGA Cosmic COSV1010, Variant assessed as somatic; moderate impact.
- I35M (p.Ile35Met), gnomAD X-37782147-T-G, REVEL 0.21, CADD 3.56
- P37A (p.Pro37Ala), ExAC rs782057051, gnomAD rs782057051, REVEL 0.28, CADD 0.00
- P37L (p.Pro37Leu), gnomAD X-37782152-C-T, REVEL 0.34, CADD 0.09
- P37P (p.Pro37Pro), rs1556464568, gnomAD X-37782153-T-C, CADD 0.62
- K38R (p.Lys38Arg), gnomAD X-37782155-A-G, REVEL 0.22, CADD 1.87
- F39L (p.Phe39Leu), NCI-TCGA Cosmic COSV1010, NCI-TCGA Cosmic COSV6608, Variant assessed as somatic; moderate impact.
- F40I (p.Phe40Ile), rs1556464576, ClinGen CA412972629, ClinVar RCV003622604, gnomAD rs1556464576, AlphaMissense 0.69, MetaLR 0.65, Uncertain significance, Granulomatous disease, chronic, X-linked
- F40L (p.Phe40Leu), NCI-TCGA TCGA novel, gnomAD rs1556464576, Uncertain significance
- F40V (p.Phe40Val), gnomAD rs1556464576, REVEL 0.35, AlphaMissense 0.69, Uncertain significance
- Y41* (p.Tyr41Ter), rs1928965653, ClinGen CA412972643, ClinVar RCV001907973, Ensembl rs1928965653, CADD 31.00, Pathogenic, in CGDX
- Y41C (p.Tyr41Cys), NCI-TCGA TCGA novel, REVEL 0.83, CADD 25.10, Variant assessed as somatic; moderate impact., in CGDX
- Y41D (p.Tyr41Asp), rs151344453, ClinGen CA219681, ClinVar RCV000059234, UniProt VAR 025613, AlphaMissense 0.97, MetaLR 0.92, not provided
- Y41T (p.Tyr41Thr), gnomAD X-37782159-CT-C, CADD 17.90
- Y41Y (p.Tyr41Tyr), rs1928965653, gnomAD X-37782165-C-T, CADD 2.10
- T42R (p.Thr42Arg), rs2519190931, ClinGen CA412972648, ClinVar RCV003064693, Uncertain significance, Granulomatous disease, chronic, X-linked
- T42K (p.Thr42Lys), gnomAD X-37782167-C-A, REVEL 0.79, CADD 23.80
- T42T (p.Thr42Thr), rs782767053, gnomAD X-37782168-A-G, CADD 8.00
- R43K (p.Arg43Lys), NCI-TCGA Cosmic COSV1010, NCI-TCGA Cosmic COSV9905, Variant assessed as somatic; moderate impact.
- R43R (p.Arg43Arg), rs2146803168, gnomAD X-37782171-A-G, CADD 12.00
- L45F (p.Leu45Phe), NCI-TCGA Cosmic COSV6608, Variant assessed as somatic; moderate impact.
- L45I (p.Leu45Ile), NCI-TCGA Cosmic COSV6608, REVEL 0.47, CADD 18.10, Variant assessed as somatic; moderate impact.
- L45L (p.Leu45Leu), rs1473978630, gnomAD X-37782177-T-A, CADD 10.10
- L46F (p.Leu46Phe), NCI-TCGA Cosmic COSV6608, Variant assessed as somatic; moderate impact.
- L46I (p.Leu46Ile), NCI-TCGA Cosmic COSV6608, REVEL 0.54, CADD 22.20, Variant assessed as somatic; moderate impact.
- L46L (p.Leu46Leu), gnomAD X-37782180-T-C, CADD 9.90
- G47R (p.Gly47Arg), gnomAD X-37782181-G-A, REVEL 0.92, CADD 32.00
- G47G (p.Gly47Gly), rs1556464579, gnomAD X-37782183-G-A, CADD 21.10
- S48P (p.Ser48Pro), ExAC rs782055866, gnomAD rs782055866, REVEL 0.21, CADD 12.30
- S48* (p.Ser48Ter), gnomAD X-37783491-C-A, CADD 33.00
- S48L (p.Ser48Leu), gnomAD X-37783491-C-T, REVEL 0.22, CADD 16.10
- S48S (p.Ser48Ser), gnomAD X-37783492-A-T, CADD 7.86
- A49T (p.Ala49Thr), rs1556464851, ClinGen CA412972700, ClinVar RCV001696923, ClinVar RCV006556166, REVEL 0.64, CADD 23.50, Conflicting interpretations, not provided; Granulomatous disease, chronic, X-linked
- A49A (p.Ala49Ala), gnomAD X-37783495-A-G, CADD 4.19
- L50L (p.Leu50Leu), gnomAD X-37783498-G-A, CADD 13.20
- A51V (p.Ala51Val), Ensembl rs1602174897, REVEL 0.51, CADD 23.80
- A51T (p.Ala51Thr), gnomAD X-37783499-G-A, REVEL 0.44, CADD 22.70
- A51E (p.Ala51Glu), gnomAD X-37783500-C-A, REVEL 0.72, CADD 23.40
- A51A (p.Ala51Ala), rs782748288, gnomAD X-37783501-A-G, CADD 4.22
- p.Leu52 Ala53del, gnomAD X-37783492-AGCACT, CADD 19.20
- A53A (p.Ala53Ala), gnomAD X-37783507-C-A, CADD 12.70
- R54G (p.Arg54Gly), rs932660228, ClinGen CA412972728, ClinVar RCV003509045, Likely pathogenic, Granulomatous disease, chronic, X-linked
- R54M (p.Arg54Met), rs151344479, ClinGen CA219706, ClinVar RCV000059249, UniProt VAR 025614, AlphaMissense 1.00, MetaLR 0.96, not provided
- R54S (p.Arg54Ser), rs151344456, ClinGen CA219708, ClinVar RCV000059250, UniProt VAR 007874, AlphaMissense 1.00, MetaLR 0.94, not provided
- R54R (p.Arg54Arg), rs932660228, gnomAD X-37783508-A-C, CADD 11.00
- A55D (p.Ala55Asp), rs151344480, ClinGen CA219712, ClinVar RCV000059252, UniProt VAR 025615, AlphaMissense 1.00, MetaLR 0.95, not provided
- A55A (p.Ala55Ala), rs1556464863, gnomAD X-37783513-C-T, CADD 12.30
- P56T (p.Pro56Thr), gnomAD X-37783514-C-A, REVEL 0.84, CADD 24.40
- P56S (p.Pro56Ser), gnomAD X-37783514-C-T, REVEL 0.71, CADD 22.10
- A57E (p.Ala57Glu), rs151344481, ClinGen CA219714, ClinVar RCV000059253, ClinVar RCV000815331, AlphaMissense 0.99, MetaLR 0.88, Pathogenic, Granulomatous disease, chronic, X-linked; not provided
- A57S (p.Ala57Ser), rs1928998515, ClinGen CA412972745, ClinVar RCV003084665, ClinVar RCV004690365, REVEL 0.88, CADD 26.40, Conflicting interpretations, not specified; Granulomatous disease, chronic, X-linked
- A57V (p.Ala57Val), TOPMed rs151344481, REVEL 0.89, AlphaMissense 0.99, Pathogenic, in CGDX
- A57A (p.Ala57Ala), rs781824754, gnomAD X-37783519-A-G, CADD 12.90
- A58V (p.Ala58Val), Ensembl rs868959821
- C59R (p.Cys59Arg), rs151344457, ClinGen CA219716, ClinVar RCV000059254, UniProt VAR 007875, AlphaMissense 1.00, MetaLR 0.85, not provided
- C59W (p.Cys59Trp), rs151344488, ClinGen CA219718, ClinVar RCV000059255, UniProt VAR 047266, AlphaMissense 1.00, MetaLR 0.84, not provided
- C59C (p.Cys59Cys), gnomAD X-37783525-C-T, CADD 13.40
- N61N (p.Asn61Asn), gnomAD X-37783531-T-C, CADD 12.00
- F62Y (p.Phe62Tyr), gnomAD X-37783533-T-A, REVEL 0.86, CADD 27.30
- F62L (p.Phe62Leu), gnomAD X-37783534-C-A, REVEL 0.74, CADD 24.30
- N63H (p.Asn63His), rs1928999111, ClinGen CA412972782, ClinVar RCV001036982, Ensembl rs1928999111, AlphaMissense 0.98, MetaLR 0.89, Uncertain significance, Granulomatous disease, chronic, X-linked
- C64R (p.Cys64Arg), rs2146804063, ClinGen CA412972791, ClinVar RCV001594442, Ensembl rs2146804063, AlphaMissense 1.00, MetaLR 0.87, Pathogenic, Granulomatous disease, chronic, X-linked
- C64S (p.Cys64Ser), gnomAD X-37783539-G-C, REVEL 0.89, CADD 24.20
- C64C (p.Cys64Cys), gnomAD X-37783540-C-T, CADD 14.20
- M65I (p.Met65Ile), rs2519192309, ClinGen CA412972805, ClinVar RCV003623613, REVEL 0.61, CADD 23.60, Uncertain significance, Granulomatous disease, chronic, X-linked
- M65L (p.Met65Leu), gnomAD X-37783541-A-C, REVEL 0.25, CADD 18.00
- M65T (p.Met65Thr), gnomAD X-37783542-T-C, REVEL 0.65, CADD 23.00
- L66P (p.Leu66Pro), ExAC rs782530132
- L68I (p.Leu68Ile), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- L69F (p.Leu69Phe), Ensembl rs912810686
- L69W (p.Leu69Trp), NCI-TCGA TCGA novel, REVEL 0.94, CADD 26.90, Variant assessed as somatic; moderate impact.
- L69S (p.Leu69Ser), rs1556464875, gnomAD X-37783552-CTTGCC, CADD 31.00
- L69L (p.Leu69Leu), gnomAD X-37783553-T-C, CADD 9.90
- P70S (p.Pro70Ser), gnomAD X-37783556-C-T, REVEL 0.94, CADD 26.20
- P70T (p.Pro70Thr), gnomAD X-37783556-C-A, REVEL 0.94, CADD 25.00
- P70P (p.Pro70Pro), gnomAD X-37783558-A-T, CADD 5.48
- V71D (p.Val71Asp), gnomAD X-37783560-T-A, REVEL 0.98, CADD 27.60
- V71V (p.Val71Val), rs1347241869, gnomAD X-37783561-C-T, CADD 9.40
- C72F (p.Cys72Phe), gnomAD X-37783563-G-T, REVEL 0.97, CADD 27.60
- C72C (p.Cys72Cys), rs782202693, gnomAD X-37783564-T-C, CADD 13.20
- R73* (p.Arg73Ter), rs137854588, ClinGen CA121236, NCI-TCGA Cosmic COSV6608, ClinVar RCV000011670, Pathogenic
- R73P (p.Arg73Pro), ExAC rs781887034, TOPMed rs781887034, gnomAD rs781887034, Uncertain significance
- R73Q (p.Arg73Gln), rs781887034, ClinGen CA412972852, NCI-TCGA Cosmic COSV6608, ClinVar RCV001950313, REVEL 0.98, CADD 32.00, Uncertain significance, Granulomatous disease, chronic, X-linked
- R73R (p.Arg73Arg), gnomAD X-37783567-A-G, CADD 12.30
- N74N (p.Asn74Asn), gnomAD X-37783570-T-C, CADD 9.77
- L75M (p.Leu75Met), ESP rs141798777, ExAC rs141798777, TOPMed rs141798777, gnomAD rs141798777, REVEL 0.77, CADD 24.80, Uncertain significance, Inborn genetic diseases
- L75V (p.Leu75Val), ESP rs141798777, ExAC rs141798777, TOPMed rs141798777, gnomAD rs141798777, REVEL 0.83, CADD 24.50
- L76M (p.Leu76Met), gnomAD X-37783574-C-A, REVEL 0.77, CADD 25.30
- S77Y (p.Ser77Tyr), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- S77S (p.Ser77Ser), gnomAD X-37783579-C-A, CADD 10.80
- F78L (p.Phe78Leu), gnomAD X-37783582-C-A, REVEL 0.34, CADD 21.80
- L79I (p.Leu79Ile), gnomAD X-37783583-C-A, REVEL 0.48, CADD 23.10
- L79F (p.Leu79Phe), gnomAD X-37783583-C-T, REVEL 0.73, CADD 23.60
- R80G (p.Arg80Gly), TOPMed rs868941131
- R80R (p.Arg80Arg), rs781784281, gnomAD X-37783588-G-A, CADD 8.33
- G81G (p.Gly81Gly), gnomAD X-37783591-T-C, CADD 13.00
- S82F (p.Ser82Phe), gnomAD rs1556464894
- S82Y (p.Ser82Tyr), gnomAD X-37783593-C-A, REVEL 0.94, CADD 24.70
- S82S (p.Ser82Ser), rs1569478708, gnomAD X-37783594-C-A, CADD 12.00
- S83V (p.Ser83Val), gnomAD X-37783592-TC-T, CADD 32.00
- S83G (p.Ser83Gly), gnomAD X-37783595-A-G, REVEL 0.36, CADD 22.50
- S83R (p.Ser83Arg), gnomAD X-37783597-T-G, REVEL 0.65, CADD 23.10
- S83S (p.Ser83Ser), gnomAD X-37783597-T-C, CADD 11.70
- A84V (p.Ala84Val), rs944314548, ClinGen CA328040543, NCI-TCGA Cosmic COSV1010, ClinVar RCV001216286, REVEL 0.29, CADD 20.20, Uncertain significance, Granulomatous disease, chronic, X-linked
- A84S (p.Ala84Ser), gnomAD X-37783598-G-T, REVEL 0.27, CADD 16.50
- A84E (p.Ala84Glu), gnomAD X-37783599-C-A, REVEL 0.59, CADD 16.50
- A84A (p.Ala84Ala), rs387906485, gnomAD X-37783600-G-A, CADD 25.90
- C85Y (p.Cys85Tyr), gnomAD X-37791976-G-A, REVEL 0.68, CADD 23.50
- C85* (p.Cys85Ter), gnomAD X-37791977-C-A, CADD 33.00
- C86F (p.Cys86Phe), TOPMed rs1165625150
- C86Y (p.Cys86Tyr), gnomAD X-37791979-G-A, REVEL 0.82, CADD 27.00
- C86* (p.Cys86Ter), gnomAD X-37791980-C-A, CADD 34.00
- S87L (p.Ser87Leu), rs375346967, ClinGen CA10383699, ClinVar RCV003052592, ClinVar RCV004070189, REVEL 0.77, CADD 24.00, Uncertain significance, Inborn genetic diseases; Granulomatous disease, chronic, X-linked
- S87* (p.Ser87Ter), gnomAD X-37791982-C-A, CADD 36.00
- T88S (p.Thr88Ser), ExAC rs782493265, TOPMed rs782493265, gnomAD rs782493265, REVEL 0.33, CADD 19.70
Public CYBB analysis runs
- CYBB analysis run — CYBB (743 variants) — completed 2026-08-18